 |
PDBsum entry 4lmm
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Protein binding
|
PDB id
|
|
|
|
4lmm
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
New conformational state of nherf1-Cxcr2 signaling complex captured by crystal lattice trapping.
|
 |
|
Authors
|
 |
Y.Jiang,
G.Lu,
L.R.Trescott,
Y.Hou,
X.Guan,
S.Wang,
A.Stamenkovich,
J.Brunzelle,
N.Sirinupong,
C.Li,
Z.Yang.
|
 |
|
Ref.
|
 |
Plos One, 2013,
8,
e81904.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
NHERF1 is a PDZ adaptor protein that scaffolds the assembly of diverse signaling
complexes and has been implicated in many cancers. However, little is known
about the mechanism responsible for its scaffolding promiscuity or its ability
to bind to multiple targets. Computational studies have indicated that PDZ
promiscuity may be attributed to its conformational dynamics, but experimental
evidence for this relationship remains very limited. Here we examine the
conformational flexibility of the NHERF1 PDZ1 domain using crystal lattice
trapping via solving PDZ1 structure of a new crystal form. The structure,
together with prior PDZ1 structures of a different space group, reveals that 4
of 11 ligand-interacting residues undergo significant crystal packing-induced
structural changes. Most of these residues correspond to the residues involved
in allosteric transition when a peptide ligand binds. In addition, a subtle
difference in ligand conformations causes the same peptide to bind in slightly
different modes in different crystal forms. These findings indicate that
substantial structural flexibility is present in the PDZ1 peptide-binding
pocket, and the structural substate trapped in the present crystal form can be
utilized to represent the conformational space accessible to the protein. Such
knowledge will be critical for drug design against the NHERF1 PDZ1 domain,
highlighting the continued need for experimentally determined PDZ1-ligand
complexes.
|
 |
|
|
|
|
 |